Julia Loh

Dr. Loh has served as Co-CEO / Chief Scientific Officer of Aurora Healthcare Corp (“Aurora”) since 2021.

Dr. Loh has over 25 years of professional experience in biomedical research, biologics manufacturing, regulatory affairs related to cell and gene therapy, medical device, and combination products. Her specialty focused on cancer immunotherapy products, from Investigational New Drug (IND) to Biologics License Application (BLA) filing. She also has comprehensive knowledge and managing skills for therapeutics in areas of oncology, regenerative medicine, and rare/orphan diseases.

Prior to join in Aurora, Dr. Loh was a VP and CTO of ConRex Pharmaceutical Corporation and a co-founder and CTO of American Genetic Testing Company. Before her time dedicated to biomedical industry, Dr. Loh spent over 10 years as a scientist of health department and institute of the U.S. government, including Food and Drug Administration and National Cancer Institute.

Dr. Loh received a Ph.D. in Microbiology and Immunology, jointly awarded by the University of Hong Kong and Sun Yat-sen University, a M.S. in Molecular and Cell Biology from Sun Yat-sen University, and a B.S. in Biochemistry, jointly awarded by Xinan University and Chinese University of Hong Kong.